Related Experiment Video
Updated: Jan 18, 2026

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
Published on: April 6, 2017
What is the role of triple inhaled therapy in COPD?
1Sarah E. Petite is an assistant professor of pharmacy practice at the University of Toledo (Ohio) College of Pharmacy and Pharmaceutical Sciences. The author has disclosed no potential conflicts of interest, financial or otherwise.
Abstract:
Triple inhaled therapy for maintenance of chronic obstructive pulmonary disease (COPD) consists of an inhaled corticosteroid, long-acting muscarinic antagonist, and long-acting beta2-agonist. Recent clinical studies evaluating triple therapy found a reduction in COPD exacerbations compared with other combination therapies. This article discusses the role of triple therapy in treating patients with COPD.
Related Concept Videos
COPD: Management Using Bronchodilators and Corticosteroids
Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
Inhaled Medications
Chronic Obstructive Pulmonary Disease-I: Introduction
Chronic Obstructive Pulmonary Disease
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:

